In this Issue:
Predictors of DFS after resection of CLM
Gemcitabine, oxaliplatin + RT in pancreatic cancer
Pemetrexed vs erlotinib in pre-treated advanced NSCLC
Soluble HER2 levels: predictive of survival
Resection vs stereotactic radiosurgery in NSCLC
USP8: a potential target in gefitinib resistance
Treating rectal cancer based on MRI staging
Patients’ expectations about RT for incurable lung cancer
Low-dose CT screening: benefits vary by pre-screening risk
Intercalated chemotherapy + erlotinib in EGFR-mutated NSCLC
Please login below to download this issue (PDF)